Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Aurobindo Pharma Ltd ( (IN:AUROPHARMA) ) has issued an announcement.
CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has received a Notice of Compliance from Health Canada for Dyrupeg, its pegylated filgrastim biosimilar, confirming that the product meets Canadian regulatory standards for safety, efficacy and quality and is highly similar to the approved reference biologic without clinically meaningful differences. The Dyrupeg approval, which follows earlier marketing authorisations in the European Union and the UK, strengthens Aurobindo’s position in the global biosimilars market, while three additional CuraTeQ biosimilar applications currently under review with Health Canada signal a deepening push into regulated biologics markets that could broaden the company’s future revenue base and competitive standing.
More about Aurobindo Pharma Ltd
Aurobindo Pharma Limited is an India-based pharmaceutical company with operations spanning active pharmaceutical ingredients, generics, and complex biologics, including through its wholly owned subsidiary CuraTeQ Biologics Private Limited. The group is expanding its presence in regulated markets such as Europe and North America with a growing focus on biosimilars and other high-value specialty medicines.
Average Trading Volume: 33,779
Technical Sentiment Signal: Strong Buy
Current Market Cap: 717.5B INR
See more data about AUROPHARMA stock on TipRanks’ Stock Analysis page.